Press releases
Browse LEO Pharma’s global press releases intended for media.
Press releases issued by our local operating companies can be viewed on our market websites.
-
LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer
LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer Ballerup, Denmark, November 3, 2025 – LEO Pharma, a leader in medical…
-
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth Ballerup, Denmark, 18 August, 2025 – In H1 2025, LEO Pharma…
-
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs Ballerup, Denmark, June…
-
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16% Ballerup, Denmark, 15 May, 2025 – In Q1, LEO Pharma continued its…
-
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership Ballerup, Denmark, 13 May 2025 — At LEO…
-
Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors
Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors Ballerup, Denmark, 5 March 2025 – At LEO Pharma’s Annual General Meeting 5 March 2025, Liisa Hurme,…
-
LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation
LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation Ballerup, Denmark, 26 February, 2025 – LEO Pharma delivered another year of strong progress in 2024, with…
-
DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases
DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases Munich, Germany, and Ballerup, Denmark, 5 February 2025 – DEBRA Research GmbH, a non-profit…
-
LEO Pharma Announces Changes to Executive Leadership
LEO Pharma Announces Changes to Executive Leadership Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr…
-
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases FOSTER CITY, Calif and BALLERUP, Denmark, January…
Media Inquiries
Head of Media
+4530502014
JEILK@leo-pharma.com
SVP, Head of Corporate Communications
+4529407016
ANMRN@leo-pharma.com
Media Manager
+4553748849
CHBUN@leo-pharma.com
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request. For updated information about clinical trials, please visit https://clinicaltrials.gov/.